GenMont BiotechTPE:3164 +0.30%82 PB Ratio is 1.07 as of Jul. 08, 2026, which is 30% below its 10-year median of 1.53. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$26.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,225 Biotechnology companies, GenMont Biotech ranks better than 82.29% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-08), GenMont Biotech's share price is NT$16.55. GenMont Biotech's Book Value per Share for the quarter that ended in Dec. 2025 was NT$15.47. Hence, GenMont Biotech's PB Ratio of today is 1.07.
Good Sign:
GenMont Biotech Inc stock PB Ratio (=1.05) is close to 10-year low of 1.03.
The historical rank and industry rank for GenMont Biotech's PB Ratio or its related term are showing as below:
TPE:3164'
s PB Ratio Range Over the Past 10 Years
Min: 1.03 Med: 1.53 Max: 2.33
Current: 1.06
During the past 13 years, GenMont Biotech's highest PB Ratio was 2.33. The lowest was 1.03. And the median was 1.53.
TPE:3164's PB Ratio is ranked better than 82.29% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs TPE:3164: 1.06
During the past 12 months, GenMont Biotech's average Book Value Per Share Growth Rate was -1.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -0.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -0.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -0.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of GenMont Biotech was 12.10% per year. The lowest was -5.80% per year. And the median was 0.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
GenMont Biotech PB Ratio Related Terms
GenMont Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for GenMont Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, GenMont Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenMont Biotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenMont Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where GenMont Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
GenMont Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
GenMont Biotech (TPE:3164) has a PB Ratio of 1.07 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GenMont Biotech and its competitors. This is 30% below median its historical median of 1.53. Over the past decade, GenMont Biotech's PB Ratio has ranged from 1.03 to 2.33. According to the industry distribution chart, GenMont Biotech ranks #217 out of 1225 companies in the Biotechnology industry, placing it in the top 17.7%.
Is GenMont Biotech's PB Ratio too high?
GenMont Biotech's current PB Ratio of 1.07 is 30% below median its 10-year median of 1.53. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 2.33. The Biotechnology industry median PB Ratio is 2.92. GenMont Biotech's value of 1.07 is 63.4% below this industry median. Based on the distribution chart, GenMont Biotech ranks #217 out of 1225 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenMont Biotech ranks #217 out of 1225 companies for PB Ratio. This places GenMont Biotech in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.92. GenMont Biotech's value of 1.07 is 63.4% below this benchmark. Historically, GenMont Biotech's own PB Ratio has ranged from 1.03 to 2.33 over the past decade. While the company's 10-year median is 1.53 vs. the industry median of 2.92, GenMont Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenMont Biotech's current PB Ratio of 1.07 is 63.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GenMont Biotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenMont Biotech's current PB Ratio is 1.07, which is 30% below median its own 10-year median of 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.24, compared to a current price of NT$16.55 — trading 36.9% below its estimated fair value. The current PB Ratio is 1.07, which is 30% below median its 10-year median of 1.53 and 63.4% below the Biotechnology industry median of 2.92. GenMont Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current PB Ratio is 1.07 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GenMont Biotech (TPE:3164) Overvalued in 2026?
Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued.
The current stock price of NT$16.55 is trading 36.9% below its estimated GF Value™ of NT$26.24.
GuruFocus considers GenMont Biotech to be Significantly Undervalued.
Key valuation signals for TPE:3164:
PB Ratio: 1.07 (30% below median its 10-year median of 1.53)
GF Value™: NT$26.24 vs. price of NT$16.55 (36.9% below fair value)
Industry Position: 63.4% below the Biotechnology median (#217 of 1225)
No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score
Get the complete analysis for TPE:3164
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3164 has been successfully added to your 
